IL-4R and TSLP Inhibitors, Inflammatory Treatment Patent Application
Summary
USPTO published patent application US20260098100A1 covering antigen binding moieties that inhibit IL-4R and TSLP pathways for inflammatory disease treatment. The application names Miguel A. Sanjuan, Sheila Gujrathi, and Ryan P. Sullivan as inventors and was filed November 10, 2025. The disclosed invention blocks IL4-IL-4R and TSLP-TSLPR interactions, targeting the same pathways addressed by approved drugs Dupilumab and Tezepelumab.
What changed
USPTO published patent application US20260098100A1 for IL-4R and TSLP inhibitors designed for inflammatory disease treatment. The application covers antigen binding moieties that block IL4-IL-4R binding and TSLP-TSLPR/IL7RĪ± interactions, with claimed efficacy comparable to or higher than monospecific antibodies Dupilumab and Tezepelumab. The invention represents potential competition in the biologic therapeutics space for inflammatory conditions. Pharmaceutical manufacturers and biotech companies developing IL-4R or TSLP-targeted therapies should monitor this application's prosecution for potential freedom-to-operate implications or licensing opportunities.
What to do next
- Monitor for patent prosecution updates
- Track application examination status
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IL-4R AND TSLP INHIBITORS AND METHODS OF USE THEREOF
Application US20260098100A1 Kind: A1 Apr 09, 2026
Inventors
Miguel A. SANJUAN, Sheila GUJRATHI, Ryan P. SULLIVAN
Abstract
Described herein is an antigen binding moiety comprising an anti-IL-4R moiety or an antigen binding portion thereof, an anti-TSLP moiety or an antigen binding portion thereof, and/or an anti-TSLPR moiety and methods of use. The antigen binding moiety described herein can block activity of IL4-IL-4R binding/interaction and/or TSLP-TSLPR/IL7RĪ± binding/interaction. In some embodiments, the antigen binding moiety described herein can block activity of TSLP and/or IL4 induced or mediated signaling, that is comparable or higher than that of a monospecific anti-IL-4R or anti-TSLP antibodies (e.g., Dupilumab and Tezepelumab, respectively) or a combination treatment (e.g., sequential or co-administration) of the monospecific anti-IL-4R and anti TSLP antibodies.
CPC Classifications
C07K 16/2866 C07K 16/244 A61K 2039/505 C07K 2317/24 C07K 2317/31 C07K 2317/55 C07K 2317/71 C07K 2317/92 C07K 2317/94
Filing Date
2025-11-10
Application No.
19384849
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.